Cure C

logocs RESEARCH INITIATIVE

Our "Towards a Cure" research team has over 25 years of research experience here in our community and has participated in hundreds of research initiatives that led to the availability of successful HIV treatments as well as medications that cure Hepatitis C.

Our team is now bringing a state of the art research initiative to our community.

We are seeking eligible patients with NASH in participate in a research protocol evaluating a new potential treatment.

Expected to be the leading reason for liver transplants by 2020 and will fuel the rising incidence of liver cancer.

25% of NAFLD patients have non-alcoholic steatohepatitis (NASH) which can lead to progressive liver fibrosis and liver failure.

Fatty Liver disease is the most common liver in disease in the world.

About 25% of adults in the US have fatty liver disease also known as Non-alcoholic Fatty Liver Disease (NAFLD).

FACTS ABOUT NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Can be seen in both adults and children.
Several factors increase a persons chance for developing NASH including:
- Being overweight
- High cholesterol
- Diabetes
Liver fibrosis and eventually cirrhosis may be expected but who progresses and the rate of the progression is unclear.
NASH is often “silent” and most people have no symptoms until there is significant liver damage.

DIAGNOSIS AND TREATMENT

It is imperative to distinguish fatty liver disease (NAFLD) from non-steatohepatitis (NASH).
Simple blood test unfortunately will not tell the difference. Diagnosis can only be confirmed by liver biopsy.
A special ultrasound called Fibroscan, can help to tell how much fibrosis has occurred if any.
Adequate treatments are not available - diet, exercise and avoidance of alcohol should be done by all but adherence and response to these interventions are suboptimal.

It’s Time For Cure C Consortium To Step Up!